What's in Glaukos Corporation's pipeline?

Glaukos Corporation has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Glaukos Corporation's portfolio?

Top competitors by shared drug class: , ABBVIE, Chi Mei Medical Hospital, Energique, Inc., Exela Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/glaukos.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Glaukos Corporation — Portfolio Competitive Intelligence Brief

Glaukos Corporation (GKOS) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

GKOS (NYSE) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Infuvite Pediatric	RIBOFLAVIN	marketed	Vitamin C [EPC]	Flavin reductase (NADPH)	Neuroscience	1953-01-01

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
ABBVIE · 1 shared drug class
Chi Mei Medical Hospital · 1 shared drug class
Energique, Inc. · 1 shared drug class
Exela Pharma · 1 shared drug class
Faculdade de Medicina do ABC · 1 shared drug class
Hippocration General Hospital · 1 shared drug class
Jun Gong, MD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Glaukos Corporation:

Cite this brief

Drug Landscape (2026). Glaukos Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/glaukos. Accessed 2026-05-13.